Loading patent…
AssigneeRemegen Co., Ltd.
InventorsJianmin Fang, Yuanhao Li, Marie M. Zhu, Jing Jiang, Yuelei Shen, Shenjun Li, Wenting Luo, Xiaoping Zhang, Lili Wang, Ling Wang, Qinbin Zhang, Fang Yang
Estimating the term…
Provided are an antibody targeting Claudin 18.2, an antibody-drug conjugate, and use thereof in treatment of cancer. Also provided are a nucleotide encoding the Claudin 18.2 antibody, a polynucleotide combination, an expression vector, an expression vector combination, a pharmaceutical composition comprising the Caudill 18.2 antibody and the antibody-drug conjugate, and an application thereof in preparation of a medication for treatment or prevention of cancer.
An anti-Claudin 18.2 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region have CDRs sequences identical to that of an antibody defined by the following sequences or obtained by 1-2 amino acid substitutions of the CDRs of the antibody defined by the following sequences:
Dependencies are inferred from the claim text.